Clinical Observation Of Live Combined Bifidobacterium And Lactobacillus Tablets Influencing On The Leucocyte Count In Ascites And Diarrhea In Liver Cirrhosis Patients

Background and ObjectivesHepatic cirrhosis is a common later stage in the development of chronic liver disease which is caused by a variety of reasons. The onset of hepatic cirrhosis is insidious and the progression of hepatic cirrhosis is slow. In the advanced stage the hypohepatia and portal hypertension always manifest as the main clinical symptom. Ascites due to hepatic cirrhosis which is the most prominently clinical manifestation of decompensated period results from hypohepatia and portal hypertension. There are often disturbed intestinal bacteria, increased intestinal permeability, bacterial translocation and low immune function in liver cirrhosis patients.They can lead high leucocyte count in ascites and diarrhea. The ascetic leucocyte count and ascetic polymorphonuclear cell count occupy an extremely important position in the diagnosis of spontaneous bacterial peritonitis (SBP).Probiotics can regulate the intestinal flora, maintain intestinal micro-ecological balance and regulate the immune function. At present reports about probiotics influencing on the leucocyte count in ascites and diarrhea in liver cirrhosis patients are less. For the guidance of safe and rational use of probiotics and to provide clinical evidence for SBP treatment, we observed influence on the leucocyte count in ascites and therapeutic efficacy on the diarrhea after treatment with live combined Bifidobacterium and Lactobacillus tablets (Golden Bifid) in liver cirrhosis patients.Materials and MethodsSixty-three patients who were diagnosed as ascites and diarrhea due to liver cirrhosis were analysed. These patients were hospitalized in the department of gastroenterology of the second affiliated hospital of Zhengzhou University from September2010to January2O12.The data was analysed by SPSS17.0statistical software package with paired data Mest, two independent samples t-test and independent samples of2×2contingency table x2test. P<0.05was considered as statistical significance.ResultsThe leucocyte number in ascites in the treatment group (n=31) was respectively (127.4+59.1) X10~6and (74.8±26.1) X10~6while the control group was respectively (128.4+53.7) X10~6nd (91.1±28.2) X10~6before and after treatment. In the treatment and control group, the leucocyte number was both obviously decreased after treatment (P<0.01). Between the treatment and control group the leucocyte number was not significant difference before treatment, while after treatment it was markedly decreased in the treatment group (P>0.05, P＜0.05).Diarrhea remission was as follows. In the treatment group11cases were significantly effective,16cases were effectual and4cases were unfruitful with a total efficacy rate of87%, while the control group8cases were significantly effective,13cases were effectual and11cases were unfruitful with a total efficacy rate of66%. The total efficacy rate of diarrhea remission in the treatment group was higher than the control group (P<0.05).ConclusionOn the basis of the comprehensive treatment, live combined Bifidobacterium and Lactobacillus tablets (Golden Bifid) can significantly decrease the leucocyte count in ascites and improve the symptoms of diarrhea more effectively in liver cirrhosis patients.